Monoclonal antibody hapten radiopharmaceutical delivery.
One hundred micrograms of monoclonal antibody (MoAb) CHA255 with a binding constant Kb of 4 X 10(9) was complexed with indium-111 labelled BLEDTA II, BLEDTA IV, benzyl EDTA, and an EDTA conjugate of Fab. The 24-h tumour and organ distribution of BALB/c mice bearing KHJJ tumours was studied for each compound alone, the antibody complex, and 3 h following a chelate chase of the antibody complex. Whole body biological half-life was measured for 7 days with and without a chelate chase for each antibody complex. The 24-h whole body counts dropped 20 to 60% and blood concentration fell over 89% within 3 h of administering the chelate chase. Theoretical equivalent human organ doses were calculated from the 24-h organ concentrations, effective half-life, and MIRD 11 S values (absorbed dose per cumulated activity). Liver and spleen were the target organs, with the dose ranging from 0.50 to 3.91 rads mCi-1. The reduction in organ radiation dose varied up to 95% following the chelate chase. Rapid selective renal clearance of chelate labelled radiopharmaceuticals by competitive inhibition (chelate chase) of their reversible binding to monoclonal antibodies enhances tumour imaging and improves the radiation dosimetry.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D001593:Benzyl Compounds; D004492:Edetic Acid; D006207:Half-Life; D006241:Haptens / Q000008:administration & dosage*; D006801:Humans; D007140:Immunoglobulin Fab Fragments; D007204:Indium; D007553:Isotope Labeling; D051379:Mice; D008807:Mice, Inbred BALB C; D011829:Radiation Dosage; D011868:Radioisotopes; D014916:Whole-Body Irradiation
D000911:Antibodies, Monoclonal; D001593:Benzyl Compounds; D006241:Haptens; D007140:Immunoglobulin Fab Fragments; D011868:Radioisotopes; D007204:Indium; D004492:Edetic Acid